Outcomes of Brentuximab Vedotin with or without Bendamustine and Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma: An Early Experience from Patient Access Programme in India

Abstract

Jyothi Goutham, Samrudhi Joshi, Shekar Patil, Satheesh Chiradoni Thungappa, Ravi Thippeswamy, Shashidha-ra HP, Nishit Ojha, Amey C Panchal, Yesheswini N Naik, Jayantha Balawardane and Sachin Suresh Jadhav

Hodgkin's lymphoma (HL) accounts for 30 % of all lymphomas. The primary therapy regimens ABVD or BEACOPP are frequently used for Hodgkin's lymphoma. Up to 40% of patients with advanced Hodgkin's Lymphoma (HL) experience a relapse after receiving their first therapy, despite current treatment protocols. Autologous Stem Cell Transplantation (ASCT) can produce long-lasting responses following an initial relapse in roughly 50% of patients with chemo-sensitive relapse. Patients included were both pediatric and adult with pathologically confirmed HL who have relapsed, refractory, or progressive disease after at least one line of treatment. Demographic and clinical data was collected along with details of treatment and responses to the treatment was observed. Safety assessments included evaluation of adverse events, routine hematology and serum chemistry tests. Data was analyzed in IBM SPSS Statistics V22.0. Descriptive statistics were performed, and categorical variables were expressed as percentages and continuous variables were expressed as mean. this series of 12 patients supports the potential clinical benefit of brentuximab vedotin as a therapeutic option for patients suffering relapse of HL with primary treatment and SCT, with equal response of PR in 50% patients and a PFS of 8 months.

PDF